OmniStar Financial Group Inc. Has $602,000 Stake in Eli Lilly and Company (NYSE:LLY)

OmniStar Financial Group Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 154.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 678 shares of the company’s stock after purchasing an additional 412 shares during the quarter. OmniStar Financial Group Inc.’s holdings in Eli Lilly and Company were worth $602,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter valued at $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at $36,000. Redmont Wealth Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $40,000. Morton Brown Family Wealth LLC lifted its stake in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares during the last quarter. Finally, Cedar Mountain Advisors LLC lifted its stake in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after acquiring an additional 16 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $917.86 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The firm has a market cap of $872.34 billion, a P/E ratio of 135.18, a P/E/G ratio of 2.79 and a beta of 0.42. The company’s 50-day moving average price is $921.21 and its two-hundred day moving average price is $857.37.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.